AMGOFIL 300mcg/ml
Accelerate neutrophil recovery with AMGOFIL Chemotherapy-induced neutropenia is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality, and can increase the overall cost of providing cancer therapy. Filgrastim reduces the incidence of infection related morbidity & mortality in patients with febrile neutropenia.
AMGOFIL
Generic Name: Recombinant Human Granulocyte Colony-Stimulating Factor
Indications
- First-line: For patients with nonmyloid malignancies receiving myelosuppressive chemotherapy, to reduce the risk of infection, particularly febrile neutropenia.
- Supportive therapy: In patients with acute myeloid leukemia (AML) undergoing induction or consolidation chemotherapy, to accelerate neutrophil recovery and shorten fever duration.
- Combination therapy: For patients with nonmyeloid cancers undergoing bone marrow transplantation, to reduce the duration of neutropenia and related complications, like febrile neutropenia.
- Pre-treatment: For the mobilization of autologous peripheral blood progenitor cellsprior to leukapheresis, in preparation for therapy.
- Long-term therapy: For patients with severe chronic neutropenia (congenital, cyclic, or idiopathic) to decrease the frequency and severity of neutropenia-related complications, such as fever and infections.
- Radiation exposure: For increasing survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).
Strength:
300ug/ml
Pack Size:
Single-use vial
Dosage Form:
Sterile injectable solution
Categories:
Pharmaceuticals
Therapeutic Class:
Colony Stimulating Factors